CO2022003829A2 - Moduladores de receptor alfa relacionado con estrógenos (errα) - Google Patents

Moduladores de receptor alfa relacionado con estrógenos (errα)

Info

Publication number
CO2022003829A2
CO2022003829A2 CONC2022/0003829A CO2022003829A CO2022003829A2 CO 2022003829 A2 CO2022003829 A2 CO 2022003829A2 CO 2022003829 A CO2022003829 A CO 2022003829A CO 2022003829 A2 CO2022003829 A2 CO 2022003829A2
Authority
CO
Colombia
Prior art keywords
errα
estrogen
modulators
receptor alpha
related receptor
Prior art date
Application number
CONC2022/0003829A
Other languages
English (en)
Inventor
Jaap Gerardus Henricus Lemmers
Eugen Deretey
Arthur Oubrie
Johannes Petrus Gerardus Klomp
Joseph Maria Gerardus Cals
Original Assignee
Lead Pharma Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Pharma Holding Bv filed Critical Lead Pharma Holding Bv
Publication of CO2022003829A2 publication Critical patent/CO2022003829A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a compuestos de acuerdo con la Fórmula I y las sales farmacéuticamente aceptables de los mismos. Los compuestos se pueden usar como moduladores del receptor alfa relacionado con estrógenos (ERRα) y tienen utilidad en el tratamiento de enfermedades o afecciones mediadas por ERRα. (I)
CONC2022/0003829A 2019-10-18 2022-03-29 Moduladores de receptor alfa relacionado con estrógenos (errα) CO2022003829A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19204189 2019-10-18
PCT/EP2020/079166 WO2021074365A1 (en) 2019-10-18 2020-10-16 ESTROGEN-RELATED RECEPTOR ALPHA (ERRα) MODULATORS

Publications (1)

Publication Number Publication Date
CO2022003829A2 true CO2022003829A2 (es) 2022-07-08

Family

ID=68296174

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0003829A CO2022003829A2 (es) 2019-10-18 2022-03-29 Moduladores de receptor alfa relacionado con estrógenos (errα)

Country Status (18)

Country Link
US (1) US20240150342A1 (es)
EP (1) EP4045503B1 (es)
JP (1) JP2023501081A (es)
KR (1) KR20220084355A (es)
CN (1) CN114630827A (es)
AU (1) AU2020365434A1 (es)
BR (1) BR112022006906A2 (es)
CA (1) CA3151045A1 (es)
CO (1) CO2022003829A2 (es)
ES (1) ES2970386T3 (es)
HR (1) HRP20240237T1 (es)
IL (1) IL291523B2 (es)
MA (1) MA57379B1 (es)
MX (1) MX2022004394A (es)
PL (1) PL4045503T3 (es)
RS (1) RS64986B1 (es)
WO (1) WO2021074365A1 (es)
ZA (1) ZA202203025B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117836296A (zh) * 2021-08-03 2024-04-05 百济神州有限公司 吡唑并吡啶酮化合物
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008222745A1 (en) * 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
US8846673B2 (en) * 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
CA2905935A1 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors

Also Published As

Publication number Publication date
PL4045503T3 (pl) 2024-05-06
WO2021074365A1 (en) 2021-04-22
JP2023501081A (ja) 2023-01-18
MA57379B1 (fr) 2024-02-29
US20240150342A1 (en) 2024-05-09
IL291523B1 (en) 2023-08-01
MX2022004394A (es) 2022-05-18
CA3151045A1 (en) 2021-04-22
IL291523B2 (en) 2023-12-01
ES2970386T3 (es) 2024-05-28
ZA202203025B (en) 2023-12-20
EP4045503A1 (en) 2022-08-24
EP4045503C0 (en) 2023-12-06
KR20220084355A (ko) 2022-06-21
EP4045503B1 (en) 2023-12-06
IL291523A (en) 2022-05-01
CN114630827A (zh) 2022-06-14
BR112022006906A2 (pt) 2022-07-05
RS64986B1 (sr) 2024-01-31
AU2020365434A1 (en) 2022-05-26
HRP20240237T1 (hr) 2024-05-10

Similar Documents

Publication Publication Date Title
CO2022003829A2 (es) Moduladores de receptor alfa relacionado con estrógenos (errα)
CO2021017619A2 (es) Moduladores del receptor alfa relacionado con estrógeno (errα)
SV2019005823A (es) Inhibidores de diacilglicerol aciltransferasa 2
ECSP18073726A (es) Inhibidores del enlace proteína-proteína de wdr5
CO6470866A2 (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos.
CU20110225A7 (es) Derivados de l-(piperidin-4-il)-pirazol como moduladores de gpr 119
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
PE20181366A1 (es) Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa
CL2022001710A1 (es) Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t
CO6781497A2 (es) Tratamiento para la lipodistrofia
CO2021008998A2 (es) Amidas de pirrolidina iii sustituidas
DOP2016000311A (es) Nuevos compuestos
MA39778A (fr) Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
CO2020016131A2 (es) Agonistas de tlr7
BR112018003489A2 (pt) n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
CL2021000329A1 (es) Compuestos útiles en terapia del vih
CL2020003248A1 (es) Derivados de tetrahidrotienopiridina n-sustituidos y sus usos
DOP2019000119A (es) Moduladores de ROR gamma (RORy)
PE20150674A1 (es) Azaheterociclos como inhibidores de bir2 y/o bir3
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
CO2018007756A2 (es) Nuevos derivados pirrolidina
ECSP22049906A (es) Agonistas del tlr7
DOP2011000029A (es) Compuestos de fenantrenona, composiciones y metodos
CO2021004612A2 (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento